Norprolac

Selected form

Quinagolide

Method of action: Other Gynecologicals

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Norprolac

Property	Description
Active Ingredient	Quinagolide (as Quinagolide hydrochloride)
Form	Oral Tablet
Pharmacological Class	Dopamine Receptor Agonist
General Purpose	Prolactin Secretion Inhibitor
Origin	Synthetic (Non-Ergot Derivative)

What Type of Medicine is Norprolac?

Norprolac is a prescription-only pharmaceutical preparation clinically recognized as a potent Dopamine Receptor Agonist. This medication contains the sole active ingredient, Quinagolide, which dictates its action within the endocrine system. The active substance is entirely synthetic and belongs to the distinct non-ergot subclass of dopamine agonists. This structural feature provides chemical differentiation from older treatments derived from ergot alkaloids, establishing Quinagolide as a modern, selective agent.

Composition and Form of Quinagolide

Norprolac is manufactured and distributed as a single-ingredient, solid oral tablet, designated for administration via the mouth. The preparation consists only of the active moiety, Quinagolide, alongside the necessary excipients that form the tablet matrix. This standardized oral tablet format is essential as it provides a precise and reliable method for systemic delivery. The formulation is developed for the management of elevated prolactin levels.

Norprolac’s General Purpose and Action

The general purpose of Norprolac is to function as a powerful and highly targeted Prolactin Secretion Inhibitor. This action is achieved by selectively stimulating D2 receptors, which are primarily located on cells in the anterior pituitary gland. This precise receptor activation generates a strong inhibitory signal that directly reduces the production and release of the hormone Prolactin. Quinagolide acts to reduce serum prolactin levels. Consequently, the drug’s core benefit is the predictable and effective reduction and normalization of elevated prolactin levels in the bloodstream, providing a therapeutic means to manage states resulting from prolactin excess.

What side effects are possible with Norprolac?

Possible Side Effects and Safety Information

The safety profile for Norprolac (quinagolide) is defined by officially documented adverse reactions classified by frequency and affected body system, as documented in regulatory sources.

Frequency Classification of Adverse Reactions

The most commonly documented effects are related to the Nervous System and Gastrointestinal System. Reactions are grouped based on the frequency observed in clinical data:

Very Common (ge 1/10): Headache, dizziness, nausea, vomiting, and fatigue.
Common (ge 1/100 to < 1/10): Orthostatic hypotension (a temporary fall in blood pressure upon standing), anorexia, difficulty sleeping, abdominal pain, constipation, diarrhea, nasal congestion, and muscular weakness.
Rare (ge 1/10,000 to < 1/1,000): Acute psychosis and somnolence (extreme drowsiness).

Clinically Significant Safety Constraints

The regulatory profile highlights specific constraints and rare, serious adverse reactions:

Serious Adverse Reactions: These include acute psychosis (which is documented as reversible upon discontinuation), syncope (fainting), and behavioral changes classified as Impulse Control Disorders (ICDs), such as pathological gambling and hypersexuality.
Time-Related Patterns: Most adverse reactions are officially noted as transient, dose-dependent, and tend to appear during the first days of treatment, often diminishing with continued use. Monitoring for orthostatic hypotension is specifically recommended during the first days of therapy and following dosage increases.
Safety Restrictions: The medication is contraindicated in patients with known impaired hepatic or renal function. Caution is also required in individuals with a history of psychosis or certain pre-existing severe non-coronary heart diseases.

This structure ensures a clear understanding of the documented safety spectrum, emphasizing that while initial side effects are common, usage is restricted in certain patient populations and requires caution for rare, serious events.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile for Norprolac (Quinagolide) is defined by a specific cluster of expected clinical manifestations and potential severe outcomes, as documented in official regulatory prescribing information. Overdosage is associated with gastrointestinal effects, including nausea and vomiting, and central nervous system disturbances, such as headache, dizziness, drowsiness, sleepiness, light-headedness, and hallucinations.

Severe Manifestations and Emergency Action

A Norprolac overdose is recognized as having the potential for severe physiological consequences. These risks include pronounced hypotension (significantly lowered blood pressure) and the possibility of collapse. Due to the nature of these potential severe outcomes, the regulatory documentation mandates immediate and urgent medical attention.

The official instructions require immediate telephone contact with a doctor or local Poison Control Centre. Alternatively, urgent travel to the nearest hospital Accident and Emergency department is required. This action is necessary even if there are no immediate signs of discomfort. No specific antidote for Quinagolide overdose is documented; therefore, treatment is officially stated to be symptomatic and supportive, requiring professional monitoring in a healthcare setting.

Therapeutic Uses of Norprolac

What Norprolac Treats: Main Uses and Benefits

Norprolac is a medication commonly used to help with conditions marked by increased physiological stress, specifically hyperprolactinemia (excessive levels of the hormone prolactin). The medication is relevant when supportive symptom management is appropriate for symptoms that interfere with daily functioning. It is applied in situations where additional symptomatic support is needed to address the consequences of high prolactin levels.

Key Therapeutic Domains

This treatment contributes to easing the overall symptom load linked to hyperprolactinemia. It is relevant for easing symptoms that may include menstrual irregularities, infertility, inappropriate breast-milk production (galactorrhea), and reduced libido. The medicine helps address symptom clusters that create noticeable physiological strain, offering supportive relief during phases when symptoms become more noticeable.

“Norprolac supports the patient during difficult episodes by easing distress and is used in settings marked by temporary physiological imbalance to help maintain a sense of stability.”

Quick Fact Block

Quick Fact: Relief for Functional Strain
This medication assists with supporting day-to-day comfort, particularly for symptoms that include reduced libido or sexual function in men with hyperprolactinemia.

Norprolac is applied in addressing conditions characterized by periods of heightened symptoms related to reproductive and functional areas, assists with functional support in these areas, and supports patients during episodes of heightened discomfort by easing secretory symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Norprolac?

Eligibility for Norprolac (Quinagolide) is governed by official regulatory documents that define specific patient populations permitted to use the medicine, those who must be monitored, and those who are formally contraindicated.

Contraindications and Restrictions

Norprolac is contraindicated and must not be used by patients with known hypersensitivity to quinagolide, or those with severely impaired hepatic function (liver problems) or severely impaired renal function (kidney problems). Use is also prohibited for individuals with rare hereditary disorders such as galactose intolerance.

Treatment is not recommended for pediatric patients (children and adolescents) or the elderly due to a lack of available clinical data.

Use Status in Special Populations

Population	Official Regulatory Status
Pregnancy	Discontinuation is required upon confirmation of pregnancy, unless continuation is medically justified.
Lactation	Not recommended as the medicine actively suppresses breast-milk production.
Psychotic Disorders	Use requires particular caution in patients with a history of psychotic disorders.
Severe Heart Disease	Requires close supervision and blood pressure monitoring during initial use.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The regulatory profile for Norprolac (quinagolide) is framed by the critical finding that no formal drug-drug interaction studies have been performed to date, and no interactions were reported in early clinical filings. Consequently, the official interaction information focuses on theoretical and cautionary risks based on the drug's known pharmacological activity.

Officially Documented Interaction Patterns:

Pharmacodynamic Antagonism: Co-administration with drugs possessing strong dopamine antagonistic properties, such as neuroleptic agents, is strongly discouraged. This combination is expected, on theoretical grounds, to cause a significant reduction of Norprolac's intended therapeutic prolactin-lowering effect.
Additive Hypotensive Effect: Combining Norprolac with Blood Pressure Lowering Agents may enhance the hypotensive effect due to an additive pharmacodynamic action on blood pressure.
Pharmacokinetic Caution: Caution is recommended when using Norprolac with drugs that are potent inhibitors of drug-metabolizing enzymes. This warning is required because limited data exists regarding the specific enzymes involved in quinagolide's metabolism, making potential pharmacokinetic changes difficult to predict by regulators.
Substance Interaction: The tolerability of Norprolac may be reduced by alcohol consumption, which is documented to increase the risk of dizziness.

The overall interaction structure is defined by theoretical risk assessment and pharmacodynamic considerations rather than data from dedicated drug interaction trials, as specified in regulatory documentation.

Mechanism of Action

Selective Activation of D2 Receptors

The active ingredient, Quinagolide, functions as a selective agonist of the Dopamine D2 receptor . These receptors are primarily located on the lactotroph cells in the anterior pituitary gland, which are responsible for producing prolactin ( PRL). By activating these receptors, Quinagolide enhances the natural, inhibitory signal (tonic control) that the brain exerts over these cells. This action initiates the entire mechanism, focusing on the specific molecular target that modulates the Neuroendocrine System.

Inhibition of Intracellular Signaling and Secretion

Receptor activation triggers a crucial inhibitory cascade inside the lactotroph cells. This molecular sequence, mediated by the G i protein, rapidly suppresses the enzyme Adenylyl Cyclase ( AC). The suppression of AC leads to a sharp reduction in the cellular concentration of the messenger cAMP, which is vital for hormone production and release. This inhibitory signaling sequence halts the necessary biochemical steps (synthesis and exocytosis) for PRL release. The core physiological result is the direct and sustained suppression of Prolactin secretion, consistent with the mechanism of a PRL Secretion Inhibitor.

Dosage and Administration Information

Instruction Map: How to use Norprolac — Official Administration Guidelines

This map consolidates the instructions for the use of Norprolac (Quinagolide), based on established product information and standardized drug labels.

Administration Scope

Route of administration: Oral (swallowed tablet)

Dosing schedule:

Initial Starting Dose (Days 1–3): 25 micrograms (mu g) once daily.
Intermediate Dose (Days 4–6): 50 mu g once daily.
Initial Maintenance Dose (Starting Day 7): 75 mu g once daily.
Typical Maintenance Range: 75 mu g to 150 mu g per day.
Maximum Doses: Daily doses of 300 mu g or higher may be required for some patients.

Timing in relation to meals (if applicable): Must be taken with some food (or a snack).

Preparation requirements (if applicable): None; tablets are swallowed whole with water.

Age-group administration rules:

Children/Adolescents: Experience with use is not available in this population.
Older Adults (Elderly): Experience with use is not available in this population.
Renal/Hepatic Impairment: Not recommended for use in cases of severe impairment due to a lack of dosing experience.

Missed-dose rules: If a dose is missed, it should be taken as soon as remembered, but a double dose must not be taken to compensate for the forgotten dose.

Special procedural conditions: Must be taken once daily at bedtime.

Instruction Classifications (High-Level)

Administration method type: Oral

Frequency pattern: Once daily

Regulatory basis: Standardized product characteristics and drug labels.

Use-context constraints: Mandatory slow titration phase; dose adjustment interval constraint; administration at bedtime with food.

Resulting Procedural Structure

Official step sequence:

Initiate treatment with the starter pack, taking 25 mu g orally once daily at bedtime with food for the first three days.
Increase the dose to 50 mu g orally once daily at bedtime with food for the next three days (Days 4–6).
Begin the initial maintenance dose of 75 mu g orally once daily at bedtime with food starting on day seven.
If necessary, increase the dose gradually in steps of 75 mu g or 150 mu g at intervals not shorter than one week or four weeks, respectively, until the optimal individual dose is achieved.

Connection to the overall use protocol (2–4 sentences): The protocol mandates a strictly gradual dose increase over the first six days, known as the titration phase, which is a required initial step before reaching the initial maintenance dose of 75 mu g. The core frequency of administration is established as once daily and is linked to the condition of being taken at bedtime with food. Subsequent dose modifications are governed by constrained time intervals to ensure a controlled and measured adjustment of the long-term, daily oral regimen.

Recent Clinical Evidence

Research evidence / Overview of studies for Norprolac

Evidence for Use in Hyperprolactinemia

This section summarizes the structure of research that was studied for general hyperprolactinemia (high prolactin levels), including findings derived from short-term and comparative randomized controlled trials, and pooled data in systematic reviews. The research was evaluated in multiple approaches. Studies monitored the primary biomarker of interest: the level of prolactin in the serum. Investigators also examined specific physical and functional outcomes, such as patterns of menstrual cycle changes and changes in the presence of galactorrhea.

Findings describe patterns observed in the studies where measurements of prolactin levels were observed in patients during the course of the research, often observed shifting toward the normal range. Despite the available evidence, sample sizes were modest in some of the foundational trials compared to current standards. Also, the existing body of evidence demonstrates heterogeneity in study designs.

Evidence for Use in Prolactin-Producing Tumors (Prolactinomas)

Research into prolactinomas (both micro- and macroadenomas) was evaluated in studies that tracked patients over extended follow-up periods, including long-term open-label studies and comparative studies. Studies monitored two main types of outcomes: the impact on prolactin levels and the effect on the tumor itself. Research examined changes in tumor size/volume, typically assessed using imaging methods.

For patients with larger tumors, research describes instances where stabilization or resolution of vision-related issues was associated with the study period. Comparative evidence is lacking for dedicated, large-scale randomized trials directly comparing Norprolac to all newer dopamine agonists specifically for tumor reduction as a primary outcome.

What Remains Uncertain in the Research Landscape

Key uncertainties persist in the research landscape. For instance, data for certain groups remain insufficient. Though research has been conducted, evidence quality varies across studies for certain populations, and long-term outcomes are not fully established for all subgroups. Therefore, while studies help show what has been observed so far, research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Norprolac (FAQ)

Q: What happens if I stop taking Norprolac suddenly?

Regulatory information indicates that treatment is often long-term and documents advise that the dose may need to be reduced gradually before stopping. Abruptly discontinuing the medicine could potentially lead to experiences of withdrawal symptoms, such as increased tiredness, sweating, pain, anxiety, and depression. Changes to the prescribed regimen are generally made following consultation with a healthcare provider.

Q: Can Norprolac cause weight gain or loss?

The official regulatory list of documented side effects does not specifically classify or list 'weight gain' or 'weight loss' by frequency. However, anorexia (a loss of appetite) is listed as a common effect. Some reports also list increased water retention as a possible effect that was observed in studies.

Q: What is the difference between Norprolac and other drugs for the same condition?

According to the official product information, Norprolac contains the active ingredient quinagolide, which is classified as a non-ergot derivative. This chemical classification means the active substance is synthetic and not derived from ergot alkaloids, which is the source of some older medicines used for the same purpose.

Q: What are the long-term effects of taking Norprolac for several years?

For patients undergoing long-term treatment, the official warnings mention that monitoring for rare but serious adverse events is described as being required. These events include behavioral changes known as Impulse Control Disorders (ICDs) and instances of acute psychosis. Studies tracking patients with prolactinomas have examined patients over extended periods of time.

Q: What should I do if I forget a dose of Norprolac?

The regulatory rule is that if a dose is forgotten, it is to be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. A double dose must never be taken to compensate for the forgotten dose.

Q: Why is Norprolac sometimes started at a low amount and slowly increased?

Official documents describe that the treatment is initiated gradually using a low starting dose, a process known as titration. This method is used because the effects of the medicine can lead to orthostatic hypotension, which is a temporary fall in blood pressure upon standing. Starting with a low dose is intended to help the body adjust and reduce the risk of this effect.

Q: Is it common for Norprolac treatment to be temporary?

Treatment is frequently required on a long-term basis to manage elevated prolactin levels effectively. However, the regulatory guidance states that the medicine should generally be discontinued when pregnancy is confirmed, unless a doctor determines there is a specific medical reason to continue therapy.

Q: Does Norprolac affect blood pressure?

Yes, Norprolac can cause orthostatic hypotension—a temporary drop in blood pressure when moving from sitting or lying down to standing. This effect is why blood pressure checking is described as being recommended during the initial days of treatment. Combining Norprolac with other blood pressure-lowering agents may enhance the hypotensive effect.

Q: Does Norprolac require any special monitoring or blood tests?

Official documents describe that blood pressure checking is recommended in both the sitting and standing positions during the initial days of therapy and following dosage increases. Patients and caregivers are also advised to monitor for the development of Impulse Control Disorders (ICDs) and psychotic disturbances, as these are rare but serious reported effects.

Q: Does Norprolac impact liver or kidney function?

Norprolac is contraindicated—meaning it must not be used—in patients who already have severely impaired hepatic function (liver problems) or severely impaired renal function (kidney problems). The regulatory text does not specify if the drug causes new impairment in those with previously normal function.

Q: Does Norprolac interfere with birth control pills?

Treatment with Norprolac may rapidly restore fertility in women. Therefore, for women who are not trying to become pregnant, a reliable method of contraception is advised. Some official sources suggest the use of a non-hormonal barrier method for contraception.

Q: What is the source of the active ingredient in Norprolac?

The active ingredient in Norprolac is quinagolide, which is a synthetic compound. Regulatory documents specify that it is a non-ergot derivative, meaning it is chemically synthesized and not derived from the natural ergot fungal compounds.

How should Norprolac be stored and disposed of?

How to Store and Dispose of Norprolac?

Norprolac (quinagolide) tablets must be stored according to specific regulatory conditions to maintain stability.

Storage Requirements

Norprolac must be stored at a temperature below 25 C. The medicine should be kept in the original package until use to ensure protection from light and moisture. The labeled shelf life of 5 years applies only to original, unopened boxes stored under this temperature constraint.

It is mandatory to store the medicine out of the sight and reach of children. Prohibited environments include damp or heat-prone areas such as the bathroom, near a sink, or on window sills.

Disposal Instructions

Expired or unused Norprolac must not be disposed of via wastewater or household waste. The official instruction is to ask a pharmacist for guidance on how to properly discard any leftover medicine to ensure compliance with environmental and pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.